Additionally, Bae et al. [29] suggested 1,2,3,4,6-penta-O-galloyl-β-d-glucose as a potential candidate antiviral drug to treat varicella-zoster virus (VZV)-associated diseases (e.g., chickenpox) due to its significant suppressive inhibitory effect on VZV-induced c-Jun N-terminal kinase (JNK) activation, expression of viral immediate-early 62 (IE62) protein, and VZV replication. The gene discussed is MAPK8; the disease is chickenpox.